| Ion Video Ltd (IOV) ORDINARY FULLY PAID |
Information Technology |
$29 |
Final Director's Interest Notice (J Rinarelli)
|
4 Feb 2026 9:40AM |
$0.430 |
$0.320 |
fallen by
25.58%
|
|
| Kairos Minerals Limited (KAI) ORDINARY FULLY PAID |
Materials |
$131 |
Main Hill Extension results at Mt York
|
4 Feb 2026 9:40AM |
$0.042 |
$0.039 |
fallen by
7.14%
|
|
KAI - Price-sensitive ASX Announcement
Full Release
Key Points
- Positive results received for the Main Hill Extension at Mt York.
- Mineralisation extends northwest from Main Hill.
- Upcoming Mt York mineral resource estimate (MRE) planned for CY2026.
- Significant gold assay results include 25MYDD082 and 25MYDD072.
- Mineralisation now defined over a 4.2km strike length.
- Next steps include further exploration and a prefeasibility study.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cyclopharm Limited (CYC) ORDINARY FULLY PAID |
Health Care |
$102 |
Cyclopharm Successfully Completes A$14 million Placement
|
4 Feb 2026 9:40AM |
$1.170 |
$0.845 |
fallen by
27.78%
|
|
CYC - Price-sensitive ASX Announcement
Full Release
Key Points
- Placement to raise A$14 million at A$0.95 per share.
- Strong support from existing and new institutional investors.
- A$2 million Share Purchase Plan available at A$0.95 per share.
- Funds to accelerate Technegas® commercialization in the USA.
- Development of next-generation Technegas® system supported.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Terra Metals Limited (TM1) ORDINARY FULLY PAID |
Materials |
$324 |
Resource Upgrade Drilling Continues to Confirm Thick Reef
|
4 Feb 2026 9:39AM |
$0.395 |
$0.410 |
risen by
3.80%
|
|
TM1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Second round of assay results reported for Reef 2 (Hyperion).
- Confirmation of thick, continuous titanium-vanadium-PGM-copper-gold mineralization.
- 15 reverse circulation and 1 diamond drillholes were involved in the recent phase.
- Broad mineralized envelopes contain higher-grade zones, indicating resource growth.
- Highest individual metal grades recorded to date at Reef 2.
- Significant upside potential in previously drilled areas.
- More than 50% of resource upgrade drill results still pending.
- Reef 2 is part of the Dante Project's pillar for scale and economic potential.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID |
Health Care |
$1,417 |
Completion of Placement and Institutional Entitlement Offer
|
4 Feb 2026 9:39AM |
$1.600 |
$1.505 |
fallen by
5.94%
|
|
PYC - Price-sensitive ASX Announcement
Full Release
Key Points
- PYC Therapeutics Limited completed a Placement and Institutional Entitlement Offer.
- The company raised $537 million at $1.50 per New Share.
- PYC agreed to issue approximately 85.5 million New Shares to US specialist investors to raise approximately $128 million.
- An Institutional Entitlement Offer was completed to issue approximately 273 million New Shares to raise approximately $409 million.
- The underwriting agreement for the Entitlement Offer has been satisfied, securing a minimum of $600 million.
- The funds extend PYC's cash runway to CY2030 for their drug development programs.
- A Retail Entitlement Offer will follow with the same terms as the Institutional Entitlement Offer.
- PYC Therapeutics focuses on precision medicine for genetic diseases with no existing treatment options.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ion Video Ltd (IOV) ORDINARY FULLY PAID |
Information Technology |
$29 |
Initial Director's Interest Notice (F O'Hanlon)
|
4 Feb 2026 9:39AM |
$0.430 |
$0.320 |
fallen by
25.58%
|
|
| Patagonia Lithium Ltd (PL3) ORDINARY FULLY PAID |
Materials |
$25 |
Proposed issue of securities - PL3
|
4 Feb 2026 9:39AM |
$0.100 |
$0.120 |
risen by
20%
|
|
| Patagonia Lithium Ltd (PL3) ORDINARY FULLY PAID |
Materials |
$25 |
Successful Placement to Fund Formentera Project
|
4 Feb 2026 9:38AM |
$0.100 |
$0.120 |
risen by
20%
|
|
PL3 - Price-sensitive ASX Announcement
Full Release
Key Points
- Patagonia Lithium Ltd successfully raised A$2,900,000 through a private placement.
- A total of 29 million fully paid ordinary shares will be issued at A$0.10 per share.
- The funds will be used primarily for the Formentera Project, including drilling and feasibility studies.
- Cygnet Capital Pty Limited acted as Lead Manager and Bookrunner for the placement.
- Participants in the placement will also receive one unquoted option for every two shares issued.
- Options have an exercise price of $0.16 per share and expire on 31 December 2027.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Larvotto Resources Limited (LRV) ORDINARY FULLY PAID |
Materials |
$772 |
Continued Strong Drilling Results at Freehold
|
4 Feb 2026 9:38AM |
$1.445 |
$1.490 |
risen by
3.11%
|
|
LRV - Price-sensitive ASX Announcement
Full Release
Key Points
- Continued delivery of strong drilling results at Freehold prospect.
- Exploration targets extensions of historically mined gold-antimony-tungsten mineralisation.
- Significant drill results include intersections with high gold equivalent grades.
- High-grade tungsten associated with gold-antimony mineralisation identified.
- Drilling ongoing at Freehold and parallel prospects Metz and Swamp Creek.
- Potential shown for a new underground mining centre at Freehold.
- Hillgrove project consists of a dozen exploration targets.
- Recent drilling has identified new parallel mineralised zones.
- Future work involves further drilling to test additional nearby prospects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ion Video Ltd (IOV) ORDINARY FULLY PAID |
Information Technology |
$29 |
Initial Director's Interest Notice (A Baker)
|
4 Feb 2026 9:37AM |
$0.430 |
$0.320 |
fallen by
25.58%
|
|
| VanEck 5-10 Year Australian Government Bond ETF (5GOV) |
Financials |
$88 |
Update to Fund Information
|
4 Feb 2026 9:37AM |
$51.510 |
$52.300 |
risen by
1.53%
|
|
| VanEck Australian Floating Rate ETF (FLOT) |
Financials |
$959 |
Update to Fund Information
|
4 Feb 2026 9:37AM |
$24.960 |
$25.030 |
risen by
0.28%
|
|
| VanEck Australian Corporate Bond Plus ETF (PLUS) |
Financials |
$396 |
Update to Fund Information
|
4 Feb 2026 9:37AM |
$16.920 |
$17.040 |
risen by
0.71%
|
|
| VanEck 10+ Year Australian Government Bond ETF (XGOV) |
Financials |
$382 |
Update to Fund Information
|
4 Feb 2026 9:37AM |
$49.950 |
$51.060 |
risen by
2.22%
|
|
| VanEck 1-5 Year Australian Government Bond ETF (1GOV) |
Financials |
$26 |
Update to Fund Information
|
4 Feb 2026 9:37AM |
$51.100 |
$51.440 |
risen by
0.67%
|
|
| VanEck Australian Subordinated Debt ETF (SUBD) |
Financials |
$3,403 |
Update to Fund Information
|
4 Feb 2026 9:37AM |
$25.290 |
$25.330 |
risen by
0.16%
|
|
| Vaneck Australian Fixed Rate Subordinated Debt ETF (FSUB) |
Financials |
$7 |
Update to Fund Information
|
4 Feb 2026 9:37AM |
$25.220 |
$25.400 |
risen by
0.71%
|
|
| Decidr AI Industries Ltd (DAI) ORDINARY FULLY PAID |
Consumer Staple |
$140 |
Q2 FY26 Investor Webinar
|
4 Feb 2026 9:36AM |
$0.435 |
$0.440 |
risen by
1.15%
|
|
| Ion Video Ltd (IOV) ORDINARY FULLY PAID |
Information Technology |
$29 |
ION Strengthens Board of Directors
|
4 Feb 2026 9:36AM |
$0.430 |
$0.320 |
fallen by
25.58%
|
|
IOV - Price-sensitive ASX Announcement
Full Release
Key Points
- ION Video Ltd strengthens Board of Directors with key appointments.
- Anthony Baker becomes CEO and Director; Finbar O'Hanlon joins as Head of Innovation and Director.
- Joe Rinarelli steps down from the Board but remains CFO.
- ION focuses on video superintelligence infrastructure as core technology.
- Finbar O'Hanlon returns after a decade, bringing AI and innovation expertise.
- Upcoming technology showcase webinar scheduled for 9 February 2026.
- Strategic repositioning aims to leverage AI's growing role in video data processing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brazilian Rare Earths Limited (BRE) ORDINARY FULLY PAID |
Materials |
$1,478 |
Exceptional Ore Sorting Yields and Enrichment at Monte Alto
|
4 Feb 2026 9:36AM |
$3.910 |
$5.360 |
risen by
37.08%
|
|
BRE - Price-sensitive ASX Announcement
Full Release
Key Points
- Exceptional grade enrichment achieved with >2x upgrade, increasing feed grades from 12.4% TREO to ~27% TREO.
- High-grade product obtained in single-pass processing with +27% TREO.
- Cascade ore sorting produced a +20% TREO product with recoveries of ~96–99%.
- Efficient waste rejection with ~25% feed mass rejected as waste with negligible rare earth loss.
- Ore sorting enables high-grade product at yields of +95%, supporting direct hydrometallurgical processing.
- The Monte Alto mineralisation allows for significant economic benefits with reduced capital and operating costs.
- Sensor-based sorting demonstrated potential for high recoveries and increased run-of-mine grade by 1.3x–1.7x.
- The sorting process uses multi-sensor technology combining X-ray transmission, 3D laser, and inductive sensors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Krakatoa Resources Limited (KTA) ORDINARY FULLY PAID |
Materials |
$10 |
Proposed issue of securities - KTA
|
4 Feb 2026 9:35AM |
$0.010 |
$0.008 |
fallen by
20%
|
|
| Insignia Financial Ltd (IFL) ORDINARY FULLY PAID |
Financials |
$3,132 |
Insignia Financial Half-Year 2026 Results Webcast Details
|
4 Feb 2026 9:35AM |
$4.650 |
$4.670 |
risen by
0.43%
|
|
| Krakatoa Resources Limited (KTA) ORDINARY FULLY PAID |
Materials |
$10 |
$1.25M Placement Secured to Advance Zopkhito Sb-Au Project
|
4 Feb 2026 9:35AM |
$0.010 |
$0.008 |
fallen by
20%
|
|
KTA - Price-sensitive ASX Announcement
Full Release
Key Points
- Firm commitments received to raise $1.25 million via placement.
- Placement at $0.009 per new share with free attaching option.
- Funds to support Phase 2 drilling at Zopkhito in Q2 2026.
- High-grade antimony and gold results confirmed recent exploration.
- Executive Chairman thanked Lead Managers and welcomed new shareholders.
- Placement involves 138,888,889 new shares to raise a total of $1.25 million.
- Shares issued utilize available placement capacity under ASX Listing Rule 7.1.
- Settlement and ASX quotation dates set for February 2026.
- Lead Managers receiving a 6% fee on funds raised.
- General Meeting scheduled to approve issue of Placement Options.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID |
Health Care |
$109 |
Proposed issue of securities - ILA
|
4 Feb 2026 9:34AM |
$0.390 |
$0.370 |
fallen by
5.13%
|
|
| Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID |
Health Care |
$109 |
$9m placement to advance US biodefence opportunity
|
4 Feb 2026 9:34AM |
$0.390 |
$0.370 |
fallen by
5.13%
|
|
ILA - Price-sensitive ASX Announcement
Full Release
Key Points
- Placement of 25.7 million new shares at $0.35 each to raise $9 million
- Funding secured from US-based family office and international investors
- Funds to advance Galidesivir through FDA's Animal Rule pathway
- Targeting US Government Strategic National Stockpile opportunities
- Positioning for significant upside with potential Priority Review Voucher
- Galidesivir aligns with US biodefense priorities
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.